Confirmed Exhibitors
SSO ASM 2025 Exhibitors
We’re delighted to introduce our confirmed exhibitors for SSO ASM 2025! Their participation brings together a wealth of expertise, products, and solutions that continue to drive innovation in oncology. Attendees will have the opportunity to connect with industry leaders, explore cutting-edge technologies, and discover resources that are shaping the future of cancer care and research.
Exhibitors
AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people’s lives. Our commitment is measured by the impact we make – to patients, to our communities, and to the world. Today our products help more than 60 million people living in more than 175 countries, and we are making significant advancements with a robust pipeline of potential new medicines as we look to find the treatments of tomorrow.
(https://www.abbvie.com/)
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women’s health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need.
(https://www.astellas.com/sg/)
We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
(https://www.astrazeneca.com/country-sites/singapore.html)
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.
(https://beonemedicines.com/)
Bristol Myers Squibb is a global biopharma company dedicated to discovering, developing, and delivering innovative, high-quality medicines for serious diseases, advancing science, and ensuring access. It advocates policies promoting equality, fairness, and inclusion, aiming to meet diverse patient needs and make life-changing treatments widely accessible.
(https://www.bms.com/sg)
Daiichi Sankyo is an innovative global healthcare company headquartered in Tokyo and established in 2005 through the merger of Daiichi Pharmaceutical Co., Ltd. and Sankyo Co. Ltd., two of Japan’s oldest and most prominent drugmakers with more than 120 years of experience. Daiichi Sankyo employs over 20,000 people globally with operations across Asia, North America, and Europe. Its global R&D activities leverage world-class science and technology to create new modalities and innovative medicines and deliver novel, targeted therapies to address high unmet medical needs, particularly in cancer. Daiichi Sankyo has also become a recognized leader in oncology through the development of its proprietary DXd antibody‑drug conjugate (ADC) technology, which includes Enhertu and Datroway.
(https://www.daiichisankyo.com/sg/about_us/)
Driven by our mission to provide better healthcare for all, we bring life-saving and life-changing drugs, medicines, supplements, vaccines, treatments, and medical devices to patients – bridging the inequality gap and improving patient outcomes by supporting our partners with a full range of commercial outsourcing and market expansion services.
(https://www.dksh.com/sg-en/home)
Gene Solutions is a leading biotech company in Asia-Pacific, delivering advanced genomic solutions engineered for cost-efficiency, powered by a unified cell-free DNA platform and multi-omic AI. With over two million NGS tests delivered, it is recognized for proprietary research, a world-class genomic portfolio, and CAP-accredited laboratories driving precision medicine.
(https://genesolutions.com/)
Gilead and Kite Oncology are creating the future of oncology. From ADCs and small molecules to cell therapy, our R&D programs and partnerships are focused on helping to bring more life to people with cancer and changing the way cancer is treated.
(https://www.gilead.com/)
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
(https://www.gsk.com/en-gb/locations/singapore/)
Johnson & Johnson Innovative Medicine is leading where medicine is going. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow.
(https://innovativemedicine.jnj.com/apac/)
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
(https://www.msd.com/)
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
(www.takeda.com)
Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of oncology therapeutics. The goal of our team is to build a leading biopharmaceutical company focused on improving the lives of cancer patients.
(https://stemline.com/)
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy, to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight.
(https://www.varian.com)
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
(https://www.zuelligpharma.com/)
Contact Us
For more information regarding all opportunities available, please contact us at ssoasm-partnerships@icsevents.com